Skip to main content
. 2020 Jan 16;105(9):2262–2272. doi: 10.3324/haematol.2019.235648

Figure 4.

Figure 4.

Adverse events and drug doses in patients with polycythemia vera (left) and myelofibrosis (right). The number of adverse events per patient during the study period with mean doses of pegylated interferona2 (PEG-IFNa2) and ruxolitinib (RUX). Gr. 1-2 non-hem AEs: grade 1-2 non-hematologic adverse events; gr. 3-4 non-hem AEs: grade 3-4 nonhematologic adverse events; All gr. hem AEs: All grade hematologic adverse events.